Visionary Therapeutics

Visionary Therapeutics is a biopharmaceutical company based in San Diego, California, specializing in the discovery and development of small molecule modulators for nuclear receptors. The company's primary focus is on the Retinoic acid receptor-related orphan receptor gamma (ROR gamma), a key transcription factor that regulates Th17 cell differentiation and the production of pro-inflammatory cytokines like IL-17. Utilizing a proprietary structure-based drug design platform, Visionary Therapeutics develops highly selective and potent inhibitors aimed at treating autoimmune disorders such as psoriasis and multiple sclerosis. Additionally, the company explores the potential of ROR gamma modulators in oncology applications. Their pipeline includes candidates that have progressed into early-stage clinical trials and various pre-clinical programs.